Content |
2025: Neuroimplant released for migraine management with management via app
At the end of May 2025, the Dutch company Salvia BioElectronics announced the development of the MySalvia therapeutic system for the treatment of migraine through a special neuroimplant. The device helps reduce the frequency and intensity of headache attacks. Read more here.
2024
Sales of migraine drugs in Russia for the year reached ₽3,44 billion
Russian consumers purchased antimigrenous drugs worth ₽3,44 billion in 2024. Physical sales totaled 7.3 million packages of migraine medicines, analytics firm RNC Pharma said in June 2025.
According to RNC Pharma, natural sales of the N02C group's drugs according to the EphMRA classifier showed a decrease of 1.2% in 2024 compared to 2023. In 2023, relative to 2022, the demand for antimigrants fell by 3.9% in packages.
Ruble sales of antimigrants in January-May 2025 in the retail market of Russia reached ₽1,68 billion in retail prices, including VAT. The dynamics in this pharmacological group was significantly ahead of the average market indicators and amounted to 26.7% during calculations in Russian currency.
The development of the antimigrenous drugs segment in 2025 is almost exclusively due to the switching of demand for more expensive products. The natural dynamics in the analyzed period did not exceed 1.7% in packages, which indicates the influence of the inflationary factor on the cost indicators.
There is no pronounced seasonality of sales for the analyzed group of drugs. Consistently high demand is recorded in December - in the last month of 2024, 656 thousand packages worth about ₽349 million were sold in retail.
TOP-10 of brands of antimigrenous drugs by volume of cash sales in the Russian retail market in January-May 2025:
- Sumatriptan (Teva and other companies) - 54.7% of the market, growth 13%
- Exenza (Pharmamed) - 12.2% of the market, 199% growth
- Ajovi ( Teva) - 7.1% of the market, growth of 237%
- Relpax (Viatris) - 5.8% of the market, 5% growth
- Irinex (Novartis) - 5.8% of the market, 5% growth
- Amigrenin (Abbott) - 5.0% of the market, 12% decline
- Zolmitriptan ("Northern Star") - 3.1% of the market, 21% growth
- Sumamigren ("Akrikhin") - 2.8% of the market, a decrease of 9%
- Caporiza (Sotex) - 2.2% of the market, 122% growth
- Migrepam (Binnopharm) - 0.3% of the market, 26% decline
Minimum sales of antimigrants usually occur in January-February. In March, demand usually increases - the results of March 2025 were comparable to those of December 2024, and in the summer, demand is relatively stable.[1]
Russian company released headphones to cure mental disorders
On April 19, 2024, the Russian company Neiry, together with the National Medical Research Center of PN named after V.M. Bekhtereva, presented Neiry Buds headphones that can be used for the therapy of mental disorders. It is claimed that the gadget helps in the treatment of conditions such as insomnia, anxiety, stress, migraines and various pain sensations. Read more here.
Migraine implantable device released
On February 6, 2024, the American medical device developer ShiraTronics introduced an implantable migraine treatment device in the head. The system uses neurostimulation technology to eliminate the debilitating symptoms of this ailment. Read more here.
2023
1% increase in sales of migraine drugs to 8 million packages
At the end of 2023, approximately 8 million packages of migraine drugs were sold in Russia. This is 1% more compared to the previous year, when sales were estimated at 7.9 million units. At the same time, in monetary terms, the market volume increased by 10% - from 2.7 billion rubles to 3 billion rubles. Such data are given in the AlphaRM study, the results of which were published on February 7, 2024.
According to Pharmvestnik, in 2023 the average price of packaging a migraine drug rose by 8% on an annualized basis. For comparison: in 2022, the increase in relation to the previous year was 18%, and in 2021 - about 17%. This is partly due to the appearance on the Russian market of expensive drugs for headaches (monoclonal antibodies).
The study says that in 2023, eight INNs (international non-proprietary name) from migraines presented by 23 brands were sold on the Russian market. The dominant position among them is occupied by sumatriptan - it accounts for about 76% in rubles and 92% in packages in the corresponding segment of the retail market. Sales of drugs with sumatriptan in monetary terms in 2023 increased by 6.3% compared to the previous year. There are nine brands on the Russian market offering drugs with this active ingredient.
Erenumab is in second place in the ranking of the best-selling migraine drugs in Russia, which accounted for approximately 7.6% in monetary terms in 2023. Eletriptan closes the top three with a share of about 7.3% in money. The top five also include zolmitriptan and fremanezumab with results of 5% and 3.4%, respectively. By the end of 2023, the share of all other drugs, including risatriptan (a new drug), was less than 0.5% for each.[2]
Russian pharmacists have developed and registered a new medicine for migraine
The Russian pharmacists developed and registered a migraine drug. This was Rusnano reported on March 21, 2023.
The drug "Relonova" of the company "NovaMedica" is designed to stop headache in case of migraine attacks. Read more here.
2022: Release of a new version of the migraine treatment device, for which $45 million was raised
In late August 2022, Theranica announced serial sales of an updated shoulder-worn migraine treatment device. For the wide commercial implementation of the project, the manufacturer attracted $45 million in investments. Read more here.
2021
Initiation of the use of the K.O.S. neuromodulation system for the treatment of chronic migraine
At the end of May 2021, the Swedish medical technology company Chordate Medical developed and patented a new neuromodulation technology for the treatment and prevention of chronic migraine in adult patients. The development was called K.O.S. More details here.
Reliion Announcement - Neuromodulation Systems for Migraine Treatment
In early March 2021, the company Neurolief introduced a non-invasive neuromodulation system Relivion for the treatment of migraine. This multichannel brain neuromodulation system brain is designed to treat acute migraine at home, taking into account the individual characteristics of the patient. The system completely stops the symptoms of migraine within 2 hours of application. More. here
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |